Clinical Pharmacokinetics

, Volume 32, Supplement 1, pp 50–55 | Cite as

Sertraline

Chronopharmacokinetics and the Effect of Coadministration with Food
  • Robert A. Ronfeld
  • Keith D. Wilner
  • Barbara A. Baris
Article

Summary

Two nonblinded single-dose randomised 3-way crossover studies were conducted in healthy male volunteers to determine the effect of the time of administration (morning vs evening) and the effect of food on the pharmacokinetics of sertraline tablets.

There were no significant treatment effects on the mean area under the plasma concentration-time curve (AUC), mean peak plasma sertraline concentration (Cmax), mean time to reach Cmax (tmax), mean terminal elimination half-life, or the mean elimination rate constant in either study. The results of these 2 studies show that the bioavailability and elimination of sertraline tablets are not influenced by the time of administration or administration with or without food. Thus, sertraline tablets offer the flexibility of morning or evening administration, to patients in the fasting or nonfasting state.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther 1984; 6: 592–9PubMedGoogle Scholar
  2. 2.
    Melander A, Lalka D, McLean A. Influence of food on the presystemic metabolism of drugs. Pharmacol Ther 1988; 38: 253–67PubMedCrossRefGoogle Scholar
  3. 3.
    Fujimura A, Kajiyama H, Kumagai Y, et al. Chronopharmacokinetic studies of pranoprofen and procainamide. J Clin Pharmacol 1989; 29: 786–90PubMedGoogle Scholar
  4. 4.
    Physicians’ Desk Reference. 48th ed. Montvale, NJ: Medical Economics Data Production Company, 1994Google Scholar
  5. 5.
    Greb WH, Brett MA, Buscher G, et al. Absorption of paroxetine under various dietary conditions and following antacid intake. Acta Psychiatr Scand Suppl. 1989; 350: 99–101PubMedCrossRefGoogle Scholar
  6. 6.
    Benfield P, Ward A. Fluvoxamine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986; 32: 313–34PubMedCrossRefGoogle Scholar
  7. 7.
    Wheeler SC, Vlasses PH, Dobinska MR, et al. Plasma fluvoxamine levels in fasted and fed subjects. J Clin Pharmacol 1985; 25: 463Google Scholar
  8. 8.
    Lemberger L, Bergstrom RF, Wolen RL, et al. Fluoxetine: clinical pharmacology and physiologic disposition. J Clin Psychiatry 1985; 46 (3 sec 2): 14–9PubMedGoogle Scholar
  9. 9.
    Tremaine LM, Joerg EA. Automated gas chromatographicelectron-capture assay for the selective serotonin uptake blocker sertraline. J Chromatogr 1989; 496: 423–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1997

Authors and Affiliations

  • Robert A. Ronfeld
    • 1
  • Keith D. Wilner
    • 1
  • Barbara A. Baris
    • 1
  1. 1.Pfizer Central ResearchGrotonUSA

Personalised recommendations